Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Dec 6;2024(1):505-510.
doi: 10.1182/hematology.2024000574.

Has PD-1 blockade changed the standard of care for cHL?

Thomas M Kuczmarski  1 , Ryan C Lynch  1
Affiliations
Review

Has PD-1 blockade changed the standard of care for cHL?

Thomas M Kuczmarski et al. Hematology Am Soc Hematol Educ Program. .

Abstract

The treatment paradigm for classic Hodgkin lymphoma (CHL) continues to evolve, particularly in light of the incorporation of programmed cell death protein 1 (PD-1) inhibitors into a variety of therapeutic settings. PD-1 inhibitors have demonstrated high efficacy and a favorable toxicity profile when added to a doxorubicin, vinblastine, dacarbazine chemotherapy backbone in patients with untreated CHL. PD-1 inhibitors are also effective treatment options in the relapsed/refractory setting. For patients who are pursuing autologous stem cell transplant (ASCT), pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin has shown marked efficacy and is an effective treatment regimen to administer prior to transplant. For patients who either are not eligible for ASCT or have relapsed after ASCT, pembrolizumab or nivolumab monotherapy have been well studied and demonstrate high efficacy even when patients have been exposed to numerous lines of prior therapy. As data from previous trials continue to mature and new clinical trials are conducted, PD-1 inhibitors will continue to become an integral component for successful management of CHL.

PubMed Disclaimer

Conflict of interest statement

Thomas M. Kuczmarski: no competing financial interests to declare.

Ryan C. Lynch: consultancy/honoraria: Seagen, Foresight Diagnostics, AbbVie, Janssen, Merck; research funding: TG Therapeutics, Incyte, Bayer, Cyteir, Genentech, Seagen, Rapt, Merck, Janssen.

Figures

None
Graphical abstract
Figure 1.
Figure 1.
PD-1 inhibitors for the treatment of CHL in 2024. Figures were created with BioRender.
See this image and copyright information in PMC

References

    1. Shergold AL, Millar R, Nibbs RJB. Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade. Pharmacol Res. 2019;145(3): 104258. - PubMed
    1. Ansell SM, Lesokhin AM, Borrello I, et al.. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 2015;372(4): 311-319. - PMC - PubMed
    1. Shanbhag S, Ambinder RF. Hodgkin lymphoma: a review and update on recent progress. CA Cancer J Clin. 2018;68(2):116-132. - PMC - PubMed
    1. Borchmann P, Moccia A, Greil R, et al.. Comprehensive analysis of treatment related morbidity and progression -free survival in the GHSG phase III HD21 trial. Blood. 2023;142(suppl):3057.
    1. Borchmann P, Moccia A, Greil R, et al.. Tolerability and efficacy of BrECADD versus BEACOPP in advanced stage classical Hodgkin lymphoma: GHSG HD21, a randomized study. J Clin Oncol. 2024;42(17_suppl).

MeSH terms